Organizing committee at imed.ulisboa/ffulisboa Joao Goncalves (Coordinator) and Paula Brito.

Similar documents
Course ADVANCED DRUG DELIVERY July 03-07, 2017 Faculty of Pharmacy Amphitheatre B Universidade de Lisboa, Portugal

FCT PhD Programme Medicines and Pharmaceutical Innovation (i3du)

FCT PhD Programme Medicines and Pharmaceutical Innovation (i3du)

WORKSHOP ON NUCLEAR MOLECULAR IMAGING

We welcome the participation of external academic and scientific community members. Registration is free but mandatory.

Curriculum vitae. Research Gate:

training programme in pharmaceutical medicine Translational MEDICINE

Course Agenda. Day One

KFDA Regulatory Framework on Biopharmaceuticals - Focus on Biosimilar

OVERVIEW. ibet MISSION AND OBJECTIVES

APIFARMA PORTUGUESE PHARMACEUTICAL INDUSTRY ASSOCIATION

Baek, Kyung-min. Recombinant Protein Products Division. Ministry of Food and Drug Safety

REIMAGINING DRUG DEVELOPMENT:

Introduction of Development Center for Biotechnology TAIWAN

training programme in pharmaceutical medicine clinical development

IMMUNOTHERAPY 2008: IMPLEMENTING COMBINATIONS

training programme in pharmaceutical medicine clinical pharmacology

India as an Outsourcing Frontier in Biotechnology

Biopharmaceuticals A Regulatory Perspective

Conference Calendar. healthtech.com. January High-Content Analysis January 8-11 San Francisco, CA

BioProcess Technology Consultants, Inc. Helping Clients De-Risk Biopharmaceutical Development Since 1994

Biomolecular Characterization for Rational Drug Design. Maria João Romão

Speakers Title & Biography

Diploma (Base Course) in Medicines Development

Formulário de acesso a dados do Registo Nacional de Doentes Reumáticos (Reuma.pt) da SPR

NIH-RAID: A ROADMAP Program

UNLEASH THE POWER OF PRECISION MEDICINE

Biotech Showcase 2016

2009 INVESTOR DAY. BioPharmaceuticals. Ken Frank President BioPharmaceuticals December 17, Sustainable, Profitable Growth

SPEED UP YOUR TIME TO MARKET

CONTRACT RESEARCH SERVICES

Update on the new immunogenicity guideline in the EU

5 key characteristics

On the complexity of production planning and scheduling in the pharmaceutical industry: the Delivery Trade-offs Matrix

Nonclinical Data to Support FIH Clinical Trials for Cancer Immunotherapies. Whitney S. Helms, PhD IOM, February 29,2016

Pharmacy. i3l PHARMACY BACHELOR PROGRAM. The architect of drugs. Improving the Quality of Life

Week 1: Discovery Biology Basic knowledge and tools used in Research and Development

Scientific Program. Thursday, November 16

AT A GLANCE. inventivhealthclinical.com

BioProcess Technology Group. Helping Clients De-Risk Biopharmaceutical Development Since 1994

NIAID Resources to Facilitate Medical Countermeasure Development

Konica Minolta to Acquire Invicro (US)

BIOLOGICS & PROCESS TECHNOLOGY MASTER CLASS

EXPERT COLLECTION. Explore our leading medical review series

Handbook of Research on

Integration of FDSS7000 into a modular robotic system for Open Innovation drug discovery

Milano, September 7 th 2016

Reform of Biological Products Review with a Focus on CMC

The EIMPack Project. The Economic Impact of the Packaging and Packaging Waste Directive

Gene therapy. Findings by Alert

Characterization of antiproliferative potential and biological targets of a copper

Master of Science in Translational Biotechnology

Individualised medicine: regulatory challenges

FDA Perspective on the Preclinical Evaluation of Biological Therapies for Cancer

Pharmaceutical Toxicology: Toxicology in the Nonclinical Development of Drugs and Biologics. December 3-4, 2012 PERI Training Facility ~ Arlington, VA

i3du - PhD Programme in Medicines and Pharmaceutical Innovation First Report January 2015 June 2016 Faculty of Pharmacy, Universidade de Lisboa

Global Development Challenges: Classical and Advanced Therapy Medicinal products

leading the way in research & development

Your partner for successful biopharmaceutical development and approval

Multidisciplinary master and doctoral programmes at the University of Lisbon

CMC Strategy Forum Japan November Piyanan Boonprasirt Bureau of Drug Control Thailand Food and Drug Administration

Successful Academia-Pharma Collaboration Drug Discovery and Clinical Development

BIOPHARMACEUTICALS Availability, Diffusion, Sustainability. Massimo Riccaboni University of Florence & CERM, Rome

9:15-9:30 WELCOME Paula Alves (Conference Chair) & Lino Ferreira (SPCE-TC President)

School of Pharmacy TEMPLE UNIVERSITY

"From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia

Leading The Way in Life Science Technologies. Planning Calendar

Post-Baccalaureate Program in Pharmaceutical Science. Accelerate your career

Senior Regulatory Affairs Executive AREAS OF EXPERTISE

Sharmila et al. International Journal of Drug Regulatory Affairs; 2017, 5(1), ISSN: Available online at

Roche in Australia Innovation Leader

Implications for Preclinical and Clinical Programs. Novartis Pharmaceuticals Oncology Business Unit June 2, 2011

Leading The Way in Life Science Technologies. Planning Calendar

A Physician s consideration towards Biosimilars. João Eurico Fonseca

FACULTY OF PHARMACY UNIVERSIDADE DE LISBOA

1201 Maryland Avenue SW, Suite 900, Washington, DC ,

Agreed with W. Cornell Graduate Program and Tri-I

Specialty Lab Services. Deep science at scale

Is a Career in the. Pharmaceutical. Check out our online Student Center to find out more:

Biosimilar Monoclonal Antibodies: Registration Requirements. Henry M. J. Leng

Biosimilars: The Impact on Academic Pharmacy

Setting the Scene - Industry. Regulatory Science. Merete Schmiegelow Senior Director, Regulatory Policy

Non-clinical documentation Overview of Requirements

Presidential Commission for the Study of Bioethical Issues 2 nd meeting September

Regulatory Issues and Drug Product Approval for Biopharmaceuticals

Rare diseases in the 7th EU Framework Programme for Research and Technological Development

Introduction to Drug Design and Discovery

Biosimilar Development Clinical Investigator Considerations

Healthcare. Healthcare. The Centre for Process Innovation. From innovation to commercialisation

The importance of interchangeability in the procurement of medications: Biosimilar case

CERTIFICATE IN BIOPHARMACEUTICALS

Considerations in Product Development with Advanced Therapies and Cancer Vaccines

The Power to Cure: Therapeutic Innovation in Academia

PCWP/HCWP Workshop on personalised medicines: role of patients, consumers and healthcare professionals

Ondaplanetária Presentation

MASTER IN PHARMACEUTICAL SCIENCES (Thesis Track)

EARLY DRUG DEVELOPMENT CONSULTANCY & SERVICES CLINICAL RESEARCH SOLUTIONS

EMA s role & responsibility for the development of modern/advanced therapies

IR Presentation template [SA, JA, sector]

Recent years have witnessed an unprecedented

Transcription:

PhD Programme in Medicines and Pharmaceutical Innovation Course BioPharmaceuticals and Advanced Therapies Lisbon, 18, 19, 20 and 25, 26 September 2017 Faculty of Pharmacy Amphitheatre B Universidade de Lisboa, Portugal Organizing committee at imed.ulisboa/ffulisboa Joao Goncalves (Coordinator) and Paula Brito. The FCT PhD Programme in Medicines and Pharmaceutical Innovation (i3du; http://www.ff.ul.pt/phd3duul/) trains students in target discovery, drug design, preclinical development, and drug safety, bridging the translational gap from discoveries on disease targets and mechanisms into novel diagnostic and therapeutic agents. Programme The Course on BioPharmaceuticals and Advanced Therapies is part of the PhD Programme in Medicines and Pharmaceutical Innovation (i3du), provides an overview of both classical and biotechnology derived medicinal products and on the pathways used for scientific advice, clinical trials and marketing authorizations in Europe. The course will also cover in detail the particular requirements for the CMC section, comparability packages and important safety procedures. The particular aspects of the non-clinical and clinical development of biopharmaceuticals will be presented. Case studies discussing how to develop proteins or cell therapies, such as monoclonal antibodies will illustrate the approach taken to identify benefit/risk ratio. An overview will be given on the most essential issues relating to Advanced Therapy Medicinal Products (ATMPs). A detailed presentation of the specific considerations for the development of biosimilar medicinal products, will be given during the course. The training program welcomes the participation of external academic and scientific community members. The course will be held at the Research Institute for Medicines (imed.ulisboa), Faculdade de Farmácia, Universidade de Lisboa, in Lisbon, 18-20, 25 and 26 September 2017. The training program is aimed at PhD students, but welcomes the participation of external academic and scientific community members. Registration (https://goo.gl/forms/ybc0rjlkdo4xpiwa3) is free but mandatory. 1

September 18, 2017 1. Drug Discovery and Development 9:30h The different classes of biopharmaceuticals 10.30h Discovery of Antibodies by Phage Display Soraia Oliveira - 11:30h Microfluidics as a discovery and diagnostic tool for biopharmaceuticals Joao Pedro Conde INESC-MN and Department of Bioengineering. Instituto Superior Técnico 14:00h Biopharmaceutical discovery in cancer Antonio Duarte- Faculdade Medicina Veterinária da Universidade de Lisboa 15:00h Steps in the discovery of a vaccine: the case of HIV Nuno Taveira Instituto Superior de Ciências da Saúde Egas Moniz Research Institute for Medicines (imed.ulisboa), September 19, 2017 2. Discovery and Therapeutic Applications of Biopharmaceuticals 9:30h Stem cell systems and 3D technologies: Possible application in biopharmaceuticals toxicology Joana Miranda, Research Institute for Medicines (imed.ulisboa), 10.30h In vivo models for biopharmaceutical discovery Sandra Aguiar- Faculdade Medicina Veterinária da Universidade de Lisboa 11:30h Antibody Drug Conjugates Pedro Gois, Research Institute for Medicines (imed.ulisboa), Faculty of Pharmacy, Universidade de Lisboa 14:00h The concept and advancements of Immunotherapy 2

15:00h Biopharmaceutical therapy in autoimmune diseases Jose Alves - NOVA Medical School / CEDOC, Lisbon. Director of Internal Medicine Dept. Fernando Fonseca Hospital September 20, 2017 3. Production and development aspects of biopharmaceuticals 9:30h Production methodologies for biopharmaceuticals and regulatory environment Maria Henriques Ribeiro, Research Institute for Medicines (imed.ulisboa), 10.30h Formulation of biopharmaceuticals Joao Nuno Moreira CNC and Faculdade Farmácia da Universidade de Coimbra 11:30h New technologies for biopharmaceutical purification Cecilia Roque - UCIBIO, REQUIMTE, Departamento de Química Faculdade de Ciências e Tecnologia Universidade Nova de Lisboa 14:00h Pre-clinical Development of Biopharmaceuticals Sofia Corte-Real TechnoPhage and Faculty of Pharmacy, Universidade de Lisboa 15:00h Methodologies for Drug Clinical Development Jose Mata Faculdade de Medicina Dentária da Univ de Lisboa September 25, 2017 4. Development Issues of Advanced Therapies 09:30h Pharmacokinetics of Biopharmaceuticals Nuno Elvas - Research Institute for Medicines (imed.ulisboa), Faculty of Pharmacy, Universidade de Lisboa 10:30h Immunogenicity of Biopharmaceuticals. 11:30h Gene therapy and applications in neurologic diseases Luís Almeida, Center for Neurosciences and Cell Biology (CNC) and Faculty of Pharmacy, Universidade de Coimbra 3

14:00h Developments of phage therapy, Research Institute for Medicines (imed.ulisboa), 15:10h Regulatory overview of advanced therapies Margarida Menezes Ferreira Infarmed and European Medicines Agency. 16:00h Discussion September 26, 2017 5. Regulatory and Industrial view of Biopharmaceuticals 10:00h First in man testing of biopharmaceuticals Beatriz Lima - Research Institute for Medicines (imed.ulisboa), 11:00h Clinical Development and Medical Affairs in the biopharmaceutical industry Eduardo Ribeiro Medical Director at Abbvie Portugal. 12:00h Cell therapy: The experience from the biopharmaceutical company. Pedro Cruz - ECBio 14:00h The case of biopharmaceutical pipeline for solid tumors Ricardo Pacheco Novartis 15:00h The entrance of biosimilars in the biopharmaceutical industry Cátia Cantante - Biogen 16:00h Discussion Assessment (i3du 1 st Year PhD students ONLY) Assessment of the course consists in the preparation and submission of a research project, 10 000 characters long (including spaces). Students are grouped to build multidisciplinary teams. Each group works throughout the week on a research project that should reflect the topic of the course, including methodologies and strategies to solve an innovative research question. The project is expected to adhere to the following general structure: a) Title; b) Conceptual hurdle and innovative idea to be tested; c) Plan and methods: d) Relevance of the project (scientific and social impact). 4

The students will select a broad topic of research and are expected to propose a specific project. This project will be evaluated according to the following criteria and weight: a) Novelty and relevance (30%); b) approach to the problem (30%); c) multidisciplinarity of the research plan (40%). 5